SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184318

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184318

Theranostics Market, By Therapeutic Area, By Technology, By End User, By Geography

PUBLISHED:
PAGES: 253 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

Theranostics Market is estimated to be valued at USD 11.4 Bn in 2026 and is expected to reach USD 28.8 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 11.4 Bn
Historical Data for: 2020 to 2024 Forecast Period: 2026 to 2033
Forecast Period 2026 to 2033 CAGR: 10.90% 2033 Value Projection: USD 28.8 Bn

The market is undergoing significant transformation, mainly driven by the rising adoption of personalized medicine, targeted therapies, companion diagnostics, molecular imaging, and precision oncology. Theranostics combines diagnostic technologies with targeted therapeutic approaches to identify disease-specific biomarkers, select appropriate patients, guide treatment decisions, and monitor therapeutic response.

The market includes a broad range of technologies such as polymerase chain reaction (PCR), immunohistochemistry, in situ hybridization, and sequencing, which support biomarker detection and patient stratification across oncology and other therapeutic areas. Growing use of radiotheranostics is further strengthening the integration of molecular imaging with targeted radiopharmaceutical therapies, particularly in prostate cancer and neuroendocrine tumors. Advances in genomic profiling, companion diagnostics, molecular imaging, and targeted drug delivery are improving the ability of healthcare providers to deliver more individualized treatment strategies.

Healthcare providers are increasingly investing in nuclear medicine infrastructure, advanced imaging systems, molecular diagnostic platforms, and specialized oncology capabilities. The expansion of PET and SPECT imaging, radiopharmaceutical production, biomarker testing, and genomic profiling is improving theranostic workflows and supporting wider clinical adoption. Hospitals and diagnostic laboratories are also strengthening their capabilities to integrate diagnostic testing with targeted therapeutic decision-making.

Market Dynamics

The market is witnessing strong momentum owing to the increasing prevalence of cancer, rising demand for personalized medicine, and growing adoption of biomarker-based diagnosis and targeted therapies. Healthcare providers are increasingly using molecular diagnostics, genomic profiling, companion diagnostics, and advanced imaging technologies to identify actionable biomarkers and select patients who are more likely to benefit from specific treatments.

The growing adoption of radiotheranostics is a major factor supporting market expansion. Radiotheranostic approaches combine molecular imaging with therapeutic radiopharmaceuticals using the same or closely related molecular targets. This approach is increasingly being adopted in areas such as prostate cancer and neuroendocrine tumors, where molecular imaging can identify eligible patients before targeted radioligand therapy is administered.

Expansion of nuclear medicine infrastructure and molecular diagnostic capabilities is also fueling market growth. Hospitals and specialized cancer centers are investing in PET and SPECT imaging, radiopharmaceutical production and handling capabilities, molecular laboratories, and multidisciplinary oncology teams. Supportive reimbursement policies for advanced diagnostic radiopharmaceuticals are further helping improve access to theranostic procedures.

The rising global cancer burden is further strengthening demand for advanced diagnostic and treatment solutions. Growing use of biomarker testing enables clinicians to identify molecular abnormalities, improve patient stratification, and select targeted therapies based on individual disease characteristics. At the same time, advances in PCR, sequencing, liquid biopsy, and genomic profiling are broadening the role of molecular diagnostics across theranostic workflows.

However, wider adoption of theranostics depends on the availability of specialized nuclear medicine infrastructure, trained healthcare professionals, reliable radioisotope production, and efficient distribution networks. Expansion of radioligand therapy is therefore expected to create opportunities for investments across radiopharmaceutical manufacturing, molecular imaging, diagnostic testing, isotope supply, and specialized treatment centers.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Theranostics Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Thermo Fisher Scientific, Inc., Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Theranostics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Theranostics Market

Theranostics Market Segmentation

  • By Therapeutic Area (Revenue, USD Bn, 2021-2033)
  • Oncology
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Others
  • Cardiovascular Diseases
  • Neurological Disorders
  • Immunological Disorders
  • Others
  • By Technology (Revenue, USD Bn, 2021-2033)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry
  • In Situ Hybridization
  • Sequencing
  • Others
  • By End User (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Diagnostic Laboratories
  • Others
  • By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Key Players
  • Thermo Fisher Scientific, Inc.
  • Beckman Coulter, Inc.
  • Focus Diagnostics
  • AmeriPath, Inc.
  • Qiagen NV
  • Myriad Genetics, Inc.
  • Agilent Technologies
  • Abbott Laboratories
  • Foundation Medicine, Inc.
  • Oxford Cancer Biomarkers, Ltd.
Product Code: CMI2043

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapeutic Area
    • Market Snapshot, By Technology
    • Market Snapshot, By End User
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Approval
  • Collaboration/Merge/Acquisition
  • Regulatory Landscape
  • PEST Analysis
  • Porter's Five Forces Analysis
  • Epidemiology
  • Robust Pipeline Analysis

4. Global Theranostics Market, By Therapeutic Area, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
      • Breast Cancer
      • Lung Cancer
      • Colorectal Cancer
      • Cervical Cancer
      • Others
  • Cardiovascular Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Neurological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Immunological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Theranostics Market, By Technology, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Polymerase Chain Reaction (PCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Immunohistochemistry
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • In Situ Hybridization
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Sequencing
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Theranostics Market, By End User, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Diagnostic Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Theranostics Market, By Region, 2021 - 2033, (USD Billion)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2022-2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Area, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
      • North Africa
      • Central Africa
      • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profile
    • Thermo Fisher Scientific, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Beckman Coulter, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Focus Diagnostics
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • AmeriPath, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Qiagen NV
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Myriad Genetics, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Agilent Technologies
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Abbott Laboratories
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Foundation Medicine, Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Oxford Cancer Biomarkers, Ltd.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!